Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments

Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management

(2012) Elias Jabbour et al.   AMERICAN JOURNAL OF HEMATOLOGY

How I treat newly diagnosed chronic phase CML

(2012) J. Cortes et al.   BLOOD

Tyrosine kinase inhibitors in acute and chronic leukemias

(2012) Maro Ohanian et al.   EXPERT OPINION ON PHARMACOTHERAPY

The rise and fall of gatekeeper mutations? TheBCR-ABL1T315I paradigm

(2011) Don L. Gibbons et al.   CANCER

Targeted therapy in GIST: in silico modeling for prediction of resistance

(2011) Marco A. Pierotti et al.   Nature Reviews Clinical Oncology

Targeted Therapies: The Rare Cancer Paradigm

(2009) Marco A. Pierotti et al.   Molecular Oncology

Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib

(2008) Navratna Vajpai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activation of tyrosine kinases by mutation of the gatekeeper threonine

(2008) Mohammad Azam et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY